Block the signal, and you starve the tumor—but the cost is real.
In the long effort to outpace cancer's return, a targeted therapy called selpercatinibe has demonstrated a remarkable ability to hold recurrence at bay in patients whose early-stage lung tumors carry a rare RET gene mutation. Presented at a major oncology gathering in 2026, the LIBRETTO-432 trial offers one of medicine's recurring dilemmas: a treatment that works with striking precision yet extracts a significant toll from those who receive it. The data invite cautious hope — the cancer retreats, but the full measure of whether lives are extended remains, for now, unwritten.
- A hazard ratio of 0.13 signals one of the more dramatic recurrence reductions seen in adjuvant lung cancer therapy, cutting two-year recurrence from 26% down to just 5%.
- The drug's benefit arrives alongside serious disruption — two-thirds of patients on selpercatinibe experienced grade 3 or higher adverse events, with liver toxicity driving the majority of complications.
- More than half of patients required dose reductions and over three-quarters needed treatment breaks, raising urgent questions about how sustainable a three-year adjuvant course truly is.
- Overall survival data remain too immature to confirm whether fewer recurrences will translate into longer lives, leaving the trial's most consequential question unanswered.
- The field is beginning to look beyond adjuvant-only strategies, with neoadjuvant and perioperative approaches emerging as potential alternatives that could reshape how resectable RET-positive tumors are managed.
At the 2026 American Society of Clinical Oncology annual meeting, researchers unveiled results from the LIBRETTO-432 trial — a study testing whether selpercatinibe, a drug targeting the RET gene mutation, could prevent lung cancer from returning after surgery or radiation in early-stage patients. The trial enrolled 151 patients over three years, randomizing them to receive either the drug or a placebo for up to three years following initial treatment.
The efficacy findings were hard to dismiss. Among the most advanced patients in the study — those with stage II or IIIA disease — two-year event-free survival reached 96% with selpercatinibe versus 71% with placebo. Across the full study population, recurrence occurred in only 5% of patients on the active drug compared to 26% on placebo, with a hazard ratio of 0.13 reflecting a substantial reduction in risk. Even brain recurrence, one of the most feared outcomes, appeared in only one selpercatinibe patient versus three on placebo.
Yet the treatment carried a significant burden. Serious adverse events occurred in 67% of selpercatinibe patients — compared to 24% on placebo — with liver enzyme elevations being the most common culprit. These toxicities were not merely statistical: 55% of patients needed dose reductions, 77% required temporary treatment interruptions, and 17% stopped the drug permanently. Most serious events resolved after discontinuation, but the disruption was real and sustained.
Clinicians acknowledged both the promise and the unresolved questions. The three-year treatment duration lacked strong scientific grounding, and crucially, overall survival data remained too immature to determine whether patients actually lived longer. The trial also left unexplored whether neoadjuvant or perioperative strategies — approaches gaining traction in resectable lung cancer — might achieve similar or better outcomes with a different risk profile. LIBRETTO-432 marks a meaningful step forward for this molecularly defined population, but the full arc of its benefit is still being written.
At the American Society of Clinical Oncology annual meeting in 2026, researchers presented results from a trial that could reshape how doctors treat a specific subset of early-stage lung cancer patients. The LIBRETTO-432 study tested whether a targeted drug called selpercatinibe, given after surgery or radiation, could prevent cancer from returning in people whose tumors carried a mutation in the RET gene—a relatively rare but clinically meaningful driver of lung cancer growth.
The trial enrolled 151 patients between January 2022 and March 2025, randomizing them equally to receive either selpercatinibe or placebo for up to three years following their initial local treatment. The majority of the analysis focused on 109 patients with stage II or IIIA disease, the most advanced cases in the study population. Researchers followed these patients for a median of two years, tracking whether their cancer returned, progressed, or caused death.
The results were striking. Among patients with stage II or IIIA tumors, the two-year event-free survival rate—meaning no recurrence, progression, or death—reached 96 percent in the selpercatinibe group compared to 71 percent in those receiving placebo. Across the entire study population, the figures were 97 percent versus 78 percent. In concrete terms, recurrence occurred in just four patients (5 percent) on the active drug versus twenty patients (26 percent) on placebo. The hazard ratio of 0.13 indicated a substantial reduction in risk. Brain recurrence, a particularly feared complication, appeared in one selpercatinibe patient and three placebo recipients.
But the drug came with a cost. Grade 3 or higher adverse events—the serious ones—occurred in 67 percent of patients receiving selpercatinibe compared to 24 percent on placebo. The most common problem was elevation of liver enzymes, particularly alanine and aspartate aminotransferase. Seventeen percent of selpercatinibe patients experienced grade 3 or higher ALT elevation, and 19 percent had similar AST elevation. These numbers translated into real disruptions: 55 percent of patients required dose reductions, 77 percent needed temporary treatment breaks, and 17 percent stopped the drug permanently due to toxicity. The main reasons for stopping were liver enzyme elevation and interstitial lung disease. Most of these serious events resolved after the drug was discontinued.
Clinicians reviewing the data noted both promise and caution. The adjuvant approach clearly reduced recurrence risk in this molecularly defined population, and the safety profile, while demanding, proved manageable in practice. Yet questions remained unanswered. The choice of three years as the treatment duration lacked clear scientific rationale beyond convention. More pressingly, overall survival data—the ultimate measure of whether patients actually lived longer—remained immature at the time of analysis, meaning the follow-up period was too short to draw firm conclusions. Additionally, the trial did not explore neoadjuvant or perioperative strategies, approaches increasingly used in resectable lung cancer that might offer alternatives to prolonged adjuvant therapy.
The LIBRETTO-432 results open a door for RET-mutant lung cancer patients but do not yet fully answer whether this door leads to longer life. The field will watch closely as survival data mature and as clinicians weigh the substantial toxicity burden against the clear reduction in early recurrence.
Citações Notáveis
The adjuvant approach clearly reduced recurrence risk in this molecularly defined population, and the safety profile, while demanding, proved manageable in practice.— Clinical commentary on LIBRETTO-432 results
A Conversa do Hearth Outra perspectiva sobre a história
Why does the RET mutation matter enough to test a whole new drug strategy?
RET is a driver gene—it actively pushes cancer cells to grow. When you have a RET fusion, the cancer is dependent on that signal. Block it, and you starve the tumor. The problem is that until now, we didn't have good targeted options for RET in the adjuvant setting, the period right after surgery when we're trying to prevent recurrence.
The recurrence numbers are impressive—5 percent versus 26 percent. But why is the toxicity so high?
Selpercatinibe is a kinase inhibitor. It's a blunt instrument in some ways. It hits RET hard, but it also affects other pathways, particularly in the liver. You're asking patients to take this drug for three years, and their bodies are working overtime to process it. That's why we see so much liver enzyme elevation.
Seventeen percent of patients had to stop the drug completely. Doesn't that undermine the benefit?
It's a real tension. The patients who stayed on it got tremendous benefit. But yes, one in six couldn't tolerate it long-term. And we don't know if those who stopped early still got protection, or if they're at higher risk now.
You mentioned overall survival data are immature. What does that actually mean?
It means not enough patients have died yet to know whether this recurrence prevention translates into people living longer. You can prevent cancer from coming back and still have the same life expectancy if something else kills you first. We need more time and more events to answer that.
The commentary mentioned neoadjuvant strategies as an alternative. Why wasn't that tested here?
That's the bigger strategic question. Giving treatment before surgery, or around the time of surgery, might be more effective and potentially less toxic than three years of adjuvant therapy. But this trial was designed the way it was. We'll have to wait for other studies to compare approaches.